Corporate Overview

Gemini is a clinical-stage precision medicine company developing novel therapeutic compounds to treat genetically defined AMD. Its lead candidate, GEM103, is a recombinant form of the Complement Factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health. Variations in the gene that encodes CFH strongly correlate with an increased risk of developing AMD.

Latest News

View all news

Latest Presentation

Latest Events

View All Events